嗜酸性食管炎综述
嗜酸性食管炎(EoE)是慢性免疫介导的食管炎症,在欧洲和北美估计患病率为34.4/10万。诊断需有食管功能障碍症状且活检显示每高倍视野至少15个嗜酸性粒细胞,并排除胃食管反流病等。治疗包括质子泵抑制剂、局部激素、饮食疗法和食管扩张。
要点
- 诊断需食管功能障碍症状且活检每高倍视野≥15个嗜酸性粒细胞,排除其他嗜酸性粒细胞增多原因。
- 质子泵抑制剂组织学应答率41.7%,局部激素组织学缓解率64.9%。
- 食管狭窄患者可考虑内镜下扩张治疗。
核心结论
- EoE全球患病率约34.4/10万,治疗包括质子泵抑制剂、局部激素、要素饮食和经验性食物剔除,食管扩张用于有症状的食管狭窄患者。
研究设计与样本
- 本文为综述,汇总了观察性研究的系统评价(纳入1051例EoE患者)和8项随机试验的系统评价(纳入437例EoE患者)。
主要发现
- 在1051例EoE患者的观察性研究系统评价中,质子泵抑制剂治疗的组织学应答率(活检每高倍视野<15个嗜酸性粒细胞)为41.7%,安慰剂为13.3%。
- 在437例EoE患者的8项随机试验系统评价中,局部皮质激素治疗的组织学缓解率为64.9%,安慰剂为13.3%。
关键数值与推荐
- EoE诊断标准:食管功能障碍症状(如呕吐、吞咽困难或喂养困难),食管活检每高倍视野至少15个嗜酸性粒细胞,并排除胃食管反流病或贲门失弛缓症等其他原因。
- 组织学应答定义为内镜活检每高倍视野少于15个嗜酸性粒细胞。
临床怎么用
- 对疑似EoE患者,应进行内镜活检以评估嗜酸性粒细胞计数并排除其他原因。
- 治疗可选择质子泵抑制剂、局部激素(如氟替卡松、布地奈德)、饮食疗法(氨基酸配方或经验性食物剔除),有症状的食管狭窄可考虑内镜扩张。
- 疗效评估通常需要内镜活检进行客观评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Eosinophilic esophagitis (EoE) is a chronic immune-mediated inflammatory disease of the esophagus that affects an estimated 34.4/100 000 people in Europe and North America. EoE affects both children and adults, and causes dysphagia, food impaction of the esophagus, and esophageal strictures. OBSERVATIONS: EoE is defined by symptoms of esophageal dysfunction, such as vomiting, dysphagia, or feeding difficulties, in a patient with an esophageal biopsy demonstrating at least 15 eosinophils per high-power field in the absence of other conditions associated with esophageal eosinophilia such as gastroesophageal reflux disease or achalasia. Genetic factors and environmental factors, such as exposure to antibiotics early in life, are associated with EoE. Current therapies include proton pump inhibitors; topical steroid preparations, such as fluticasone and budesonide; dietary therapy with amino acid formula or empirical food elimination; and endoscopic dilation. In a systematic review of observational studies that included 1051 patients with EoE, proton pump inhibitor therapy was associated with a histologic response, defined as less than 15 eosinophils per high-power field on endoscopic biopsy, in 41.7% of patients, while placebo was associated with a 13.3% response rate. In a systematic review of 8 randomized trials of 437 patients with EoE, topical corticosteroid treatment was associated with histologic remission in 64.9% of patients compared with 13.3% for placebo. Patients with esophageal narrowing may require dilation. Objective assessment of therapeutic response typically requires endoscopy with biopsy. CONCLUSIONS AND RELEVANCE: EoE has a prevalence of approximately 34.4/100 000 worldwide. Treatments consist of proton pump inhibitors, topical steroids, elemental diet, and empirical food elimination, with esophageal dilation reserved for patients with symptomatic esophageal narrowing.
引用
- Muir A, Falk GW. Eosinophilic Esophagitis: A Review. JAMA. 2021. PMID: 34609446. doi:10.1001/jama.2021.14920
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。